Cancer-related patient characteristics associated with risk of OSA included lung cancer (95% CI: [1.0, 1.0]), prostate cancer (95% CI: [0.79, 0.95]), hematologic cancer (95% CI: [0.73, 0.96]), metastatic disease (95% CI: [0.69, 0.96]), and history of RT-HNT (95% CI: [0.72, 0.91]); in the breast cancer subgroup, prior use of aromatase inhibitors (95% CI: [0.74, 1.0]) also increased risk of OSA. Here, CYP19A1 is linked to metastatic neoplasm.